Search

everythinglearnresearchcommunity

for

Search:↓

Rapamycin treatment helps reduce brain inflammation and symptoms of mitochondrial disease by blocking specific pathways in mice.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.

Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Akt2 protein is essential for normal cell division in early mouse embryos.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

miR-3606-3p reduces skin fibrosis by blocking key signaling pathways.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Entospletinib effectively prevents eye and skin GVHD in mice.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

TCDD reduces EGF receptors in the liver, affecting growth and development.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Janus kinase inhibitors may help treat lichen planopilaris.